# Rusfertide

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/rusfertide
Canonical HTML page: https://getfinancebrief.com/entity/rusfertide

## Timeline

- **2026-02-25**: Institutional Exit Revealed — 13F filings reveal a $170 million divestment by a major institutional fund.
- **2026-01-20**: 120% Gain Milestone — PTGX stock reaches a 120% gain milestone from its 52-week low.
- **2025-11-01**: J&J Partnership Milestone — Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
- **2025-06-15**: Phase 3 Data Release — Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.

## Recent coverage (1 stories)

### Protagonist Stock Surges 120% as Major Fund Reveals $170 Million Exit
2026-02-25 21:49:49 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Full story: https://getfinancebrief.com/story/protagonist-therapeutics-stock-surge-institutional-exit

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.